MassDevice.com +5 | The top 5 medtech stories for June 7, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Court approves Halt Medical’s bankruptcy sale A Delaware state judge this week approved the bankruptcy sale of Halt Medical designed to keep its Acessa uterine fibroid treatment on the market. The Brentwood, Calif.-based women’s health company filed for Chapter 11 bankruptcy protection in April, citing assets valued at $2.2 million as of March 31 but liabilities of about $156.3 million, including a $497,000 severance payment to former chief executive Jeffrey Cohen. Read more 4. Amaranth Medical looks to recapture the potential of bioresorbable scaffolds Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s Absorb, have been plagued with a myriad of troubling data suggesting that the technology is linked to thrombosis and target lesion failure. Read more...
Source: Mass Device - Category: Medical Devices Authors: Tags: News Well Plus 5 Source Type: news